Graham Parry
Stock Analyst at Citi
(1.76)
# 3,630
Out of 4,662 analysts
236
Total ratings
59.3%
Success rate
0.2%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,800p | 12,050p | +47.72% | 13 | Aug 18, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 330.00 → kr 310.00 | kr 292.75 | +5.89% | 7 | Aug 7, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Buy | n/a | $127.12 | - | 53 | Aug 7, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 2,100p | 1,916p | +9.60% | 53 | Jul 29, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | n/a | $367.40 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €85.00 → €80.00 | €78.56 | +1.83% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Maintained: Buy | n/a | $45.83 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Maintained: Sell | $19 | $52.88 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $160.31 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | €10.08 | n/a | 1 | Sep 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 358p → 612p | 358p | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $88 | $147.60 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $50 | $28.24 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $58.20 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $34.11 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $4.90 | n/a | 1 | Oct 26, 2017 |
AstraZeneca PLC
Aug 18, 2026
Maintained: Buy
Price Target: 17,800p
Current: 12,050p
Upside: +47.72%
Novo Nordisk A/S
Aug 7, 2026
Maintained: Hold
Price Target: kr 330.00 → kr 310.00
Current: kr 292.75
Upside: +5.89%
Novartis AG
Aug 7, 2026
Maintained: Buy
Price Target: n/a
Current: $127.12
Upside: -
GSK plc
Jul 29, 2026
Maintained: Hold
Price Target: 2,100p
Current: 1,916p
Upside: +9.60%
Roche Holding AG
Mar 10, 2026
Maintained: Buy
Price Target: n/a
Current: $367.40
Upside: -
Sanofi
Feb 20, 2026
Maintained: Hold
Price Target: €85.00 → €80.00
Current: €78.56
Upside: +1.83%
Sanofi
Jan 31, 2025
Maintained: Buy
Price Target: n/a
Current: $45.83
Upside: n/a
GSK plc
Dec 6, 2024
Maintained: Sell
Price Target: $19
Current: $52.88
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $160.31
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: €10.08
Upside: n/a
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 612p
Current: 358p
Upside: n/a
Mar 3, 2023
Maintained: Hold
Price Target: $88
Current: $147.60
Upside: n/a
Feb 28, 2023
Maintained: Hold
Price Target: $50
Current: $28.24
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $58.20
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $34.11
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $4.90
Upside: n/a